Skip to main content
NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.23%AUDUSD-1.17%GBPCHF+1.02%USDCHF+0.94%GBPNZD+0.79%GBPCAD+0.79%NZDUSD-0.75%USDCAD+0.73%AUDJPY-0.69%EURGBP-0.65%USDTHB+0.64%EURAUD+0.60%EURUSD-0.60%GBPJPY+0.57%USDJPY+0.51%AUDCAD-0.47%AUDNZD-0.43%GBPTRY+0.41%CHFJPY-0.40%PLNJPY+0.39%EURCHF+0.34%GBPHKD+0.32%SGDJPY+0.32%USDTRY+0.29%NOKJPY+0.29%GBPMXN-0.28%AUDCHF-0.26%NZDJPY-0.22%CADCHF+0.22%CADJPY-0.21%NZDCHF+0.20%USDZAR+0.20%USDSEK+0.17%EURNZD+0.16%USDILS+0.16%USDMXN+0.14%USDCNH-0.14%USDNOK+0.13%EURCAD+0.13%EURZAR+0.13%GBPZAR+0.11%NZDSGD-0.11%EURSEK+0.11%CHFSEK+0.10%USDSGD+0.10%AUDNOK+0.10%EURJPY-0.09%NZDMXN-0.09%EURNOK+0.09%CHFNOK+0.08%EURHKD-0.07%GBPUSD+0.06%AUDSGD+0.06%USDDKK+0.05%EURSGD+0.04%USDCOP-0.04%USDPLN+0.04%CHFSGD+0.04%USDHKD+0.03%GBPSGD+0.02%EURPLN-0.02%NZDCAD-0.01%AUDDKK+0.01%EURCNH0.00%EURDKK0.00%EURCZK0.00%XAGUSD+0.70%GAGUSD+0.70%HG1-0.64%USOIL-0.49%UKOIL-0.33%S1-0.27%XPTUSD-0.25%COTTON-0.21%XNGUSD-0.08%GAUUSD-0.06%XAUUSD-0.06%C1+0.03%BTCUSD-0.19%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.07%ZECUSDT-0.02%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.57%XLMUSD+2.18%BCHUSDT-0.61%UNIUSD-0.74%LTCUSD+0.07%SUIUSD+1.70%HBARUSDT+1.75%TONUSD+15.77%TAOUSDT+0.27%AAVEUSD-2.45%DOTUSDT+2.87%ICPUSDT-1.58%ONDOUSDT+0.21%WLDUSDT+10.30%ARBUSDT-0.33%JUPUSDT-1.11%ATOMUSDT+1.34%INJUSDT-3.04%STXUSDT+18.01%FETUSDT+3.26%SEIUSDT+0.33%PYTHUSDT-3.04%TIAUSDT-0.07%IMXUSDT+0.97%GRTUSDT-0.44%OPUSDT-0.24%WIFUSDT+3.87%IOTAUSDT+4.03%POLUSDT-4.75%AXSUSDT+0.76%FARTCOINUSDT-0.30%EOSUSDT+4.07%DYDXUSDT+3.32%GALAUSDT+3.85%ORDIUSDT+1.22%NOTUSDT+1.55%RONINUSDT+0.06%NVDA+0.57%AAPL+0.41%GOOGL+0.93%MSFT+0.39%AMZN+0.36%TSM-0.16%SPCX+1.09%META+0.17%AVGO-1.10%TSLA+0.05%SKHY-1.36%MU+0.23%LLY-2.33%BRK-B-0.88%AMD+0.69%JPM-1.24%WMT-2.70%ASMLa-0.27%XOM+0.87%V-1.79%JNJ-1.06%INTC+3.71%0700.HK-0.23%MA-2.15%1398.HK+0.78%ABBV-0.65%CSCO+0.65%LRCX+1.44%CVX-0.08%AMAT-0.12%COST-1.54%AP2d+1.46%ORCL-0.35%BAC-0.96%CAT-1.92%KO-0.88%DELL-0.30%0005.HK-0.63%PG-2.05%HSBA.L-0.64%UNH-2.10%3988.HK+1.16%GE-1.76%1816.HK+0.48%ARM-1.37%0857.HK-0.51%0939.HK+1.34%1288.HK+0.61%PM-1.59%MS-2.43%GBPAUD+1.23%AUDUSD-1.17%GBPCHF+1.02%USDCHF+0.94%GBPNZD+0.79%GBPCAD+0.79%NZDUSD-0.75%USDCAD+0.73%AUDJPY-0.69%EURGBP-0.65%USDTHB+0.64%EURAUD+0.60%EURUSD-0.60%GBPJPY+0.57%USDJPY+0.51%AUDCAD-0.47%AUDNZD-0.43%GBPTRY+0.41%CHFJPY-0.40%PLNJPY+0.39%EURCHF+0.34%GBPHKD+0.32%SGDJPY+0.32%USDTRY+0.29%NOKJPY+0.29%GBPMXN-0.28%AUDCHF-0.26%NZDJPY-0.22%CADCHF+0.22%CADJPY-0.21%NZDCHF+0.20%USDZAR+0.20%USDSEK+0.17%EURNZD+0.16%USDILS+0.16%USDMXN+0.14%USDCNH-0.14%USDNOK+0.13%EURCAD+0.13%EURZAR+0.13%GBPZAR+0.11%NZDSGD-0.11%EURSEK+0.11%CHFSEK+0.10%USDSGD+0.10%AUDNOK+0.10%EURJPY-0.09%NZDMXN-0.09%EURNOK+0.09%CHFNOK+0.08%EURHKD-0.07%GBPUSD+0.06%AUDSGD+0.06%USDDKK+0.05%EURSGD+0.04%USDCOP-0.04%USDPLN+0.04%CHFSGD+0.04%USDHKD+0.03%GBPSGD+0.02%EURPLN-0.02%NZDCAD-0.01%AUDDKK+0.01%EURCNH0.00%EURDKK0.00%EURCZK0.00%XAGUSD+0.70%GAGUSD+0.70%HG1-0.64%USOIL-0.49%UKOIL-0.33%S1-0.27%XPTUSD-0.25%COTTON-0.21%XNGUSD-0.08%GAUUSD-0.06%XAUUSD-0.06%C1+0.03%BTCUSD-0.19%ETHUSD+7.44%USDTUSD-0.03%XRPUSD+0.63%SOLUSD-0.64%TRXUSDT+1.07%ZECUSDT-0.02%DOGEUSD-0.17%LINKUSD-2.08%XMRUSDT+0.57%XLMUSD+2.18%BCHUSDT-0.61%UNIUSD-0.74%LTCUSD+0.07%SUIUSD+1.70%HBARUSDT+1.75%TONUSD+15.77%TAOUSDT+0.27%AAVEUSD-2.45%DOTUSDT+2.87%ICPUSDT-1.58%ONDOUSDT+0.21%WLDUSDT+10.30%ARBUSDT-0.33%JUPUSDT-1.11%ATOMUSDT+1.34%INJUSDT-3.04%STXUSDT+18.01%FETUSDT+3.26%SEIUSDT+0.33%PYTHUSDT-3.04%TIAUSDT-0.07%IMXUSDT+0.97%GRTUSDT-0.44%OPUSDT-0.24%WIFUSDT+3.87%IOTAUSDT+4.03%POLUSDT-4.75%AXSUSDT+0.76%FARTCOINUSDT-0.30%EOSUSDT+4.07%DYDXUSDT+3.32%GALAUSDT+3.85%ORDIUSDT+1.22%NOTUSDT+1.55%RONINUSDT+0.06%
PT

Protagonist Therapeutics, Inc. (PTGX)

NASDAQ • Healthcare

$140.88
-$0.08 (-0.1%)
Market closed

Last close at September 30, 2026 at 20:00 UTC

Open$141.35
Day Range$140.43 - $143.67
Avg. Volume (3M)698.9K
Market Cap$9B
P/E Ratio115.5
52 Week Range
$62.24$160.81
Next EarningsIn 35 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q2 2026
Revenueeverything earned$213.4M100%
Gross Profitminus cost of goods$213.4M100%
Operating Incomeminus R&D and overhead$158.7M74%
Net Incomeminus taxes and the rest$162.8M76%

In plain terms: out of every $100 in revenue, Protagonist Therapeutics, Inc. keeps $76 as net profit.

Fundamentals & Financials

Revenue (TTM)
$281.9M
Net Income (TTM)
$82.9M
EPS (TTM)
$1.22
ROA (TTM)
9.36%
Current Ratio
21.71

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-30.2%Q1 2026-$0.69
+107.7%Q2 2026$0.05
+2.7%Q3 2026$2.29
Next

Nov 5

in 35 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Beat +2.7%

Operating cash flow came in at about $219.1 million for Protagonist Therapeutics’ second fiscal quarter of 2026, which the company reported on August 5, 2026, reflecting cash generation alongside ongoing work across its peptide-based pipeline in blood, inflammatory, and immune-mediated disorders, including programs such as rusfertide (PTG-300) and inflammatory bowel disease candidates PN-943 and PN-235. Consensus for the next period calls for EPS of $2.43 on revenue of $240.1 million.

View full earnings history

About Protagonist Therapeutics, Inc.

Protagonist Therapeutics, Inc. is a NASDAQ-listed biotechnology company focused on discovering and advancing peptide-based therapies for blood, inflammatory, and immune-mediated disorders. The company develops clinical candidates across hematological and broader blood conditions as well as inflammatory disease, and generated $46.0 million of revenue in FY2025.

Name
Protagonist Therapeutics, Inc.
CEO
Dinesh V. Patel
Website
www.protagonist-inc.com
Industry
Healthcare
Year Founded
2006
Employees
141

Today's Snapshot

AI-generated

PTGX closed slightly lower at 140.89, while its sector was weaker.

Trading Volume

Below 10d avg (852.6K)

756K

vs S&P 500 Today

Moderate Underperformance

-0.25%

Updated: September 30, 2026 at 20:06 UTC

PTGX Headlines

Tom Steyer backs select biotech names

May 2, 2026

3 min read

Fresh Valuation Checks Across Key Stocks

April 4, 2026

6 min read
View All News

Technical Indicators

2 Buy2 Neutral4 Sell
PTGX shows short-term weakness as price sits just below the ten-day averages while longer-term moving averages remain supportive, and the ADX indicates only a weak trend. Momentum and MACD readings are negative, while RSI is neutral, suggesting downward pressure without a strong directional conviction. Volatility is moderate with an ATR around 3.7 percent, and on-balance volume is tilted negative, implying distribution. The classic pivot is essentially at the current level, offering little immediate support or resistance. Technical takeaway: short-term momentum and moving averages favor a sell stance despite constructive longer-term averages.
All signals
  • EMA (5 indicators)$114.57 - $143.40
    Sell
  • RSI (14)44.60
    Neutral
  • Stochastic %K (14, 3, 3)42.78
    Neutral
  • MACD Level (12, 26)-1.33
    Sell

Peers & Related Assets

KYMRKymera Therapeutics, Inc.
$111.79+1.2%
CRNXCrinetics Pharmaceuticals, Inc.
$84.950.0%
TGTXTG Therapeutics, Inc.
$55.78-0.7%
IMVTImmunovant, Inc.
$33.78+1.0%
ALKSAlkermes plc
$40.52-0.7%
PTCTPTC Therapeutics, Inc.
$64.78-0.3%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.